ArticleDrugs in context2025

Long sustained response during second-line pembrolizumab plus lenvatinib in a patient with recurrent endometrial carcinoma: a case report.

Laura Fabbri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.